

**Explanation for Animals Listed in Category E-APHIS Form 7023: FY 1 Oct 2018 -30 Sep 2019**

Registration Number 22-R-0155

Customer number 334734

**Species: Horse**

In ninety-six (96) horses, (b) (4) [REDACTED]  
(b) (4) [REDACTED] which does not permit any deviation from the outline of production during the course of the protocol, including the administration of analgesics, systemic symptomatic or therapeutic treatment due to the possible residual contamination of the final blood product, which is used as a human therapeutic.

**Explanation for Animals Listed in Category E-APHIS Form 7023: FY 1 Oct 2018 -30 Sep 2019**

Registration Number 22-R-0155

Customer number 334734

**Species: Rabbit**

Two (2) rabbits (b) (4). Both experienced short-term lameness which was not relieved with analgesics. Pain-relieving compounds would have adversely affected the scientific validity of the study.

**Explanation for Animals Listed in Category E-APHIS Form 7023: FY 1 Oct 2018 -30 Sep 2019**

Registration Number 22-R-0155

Customer number 334734

**Species: Hamsters**

The study objective (b) (4)

The tests are required by regulation as proof of vaccine potency in each serial of vaccine produced. During the conduct of the study, four thousand four hundred ninety-six (4,496) animals experienced acute systemic toxic effects and died. Use of analgesics may invalidate the scientific validity of the results.

Six (6) animals were used to evaluate (b) (4).

Post vaccination/challenge reactions were signs expected from the (b) (4) agent. All six animals died prior to euthanasia.

**Explanation for Animals Listed in Category E-APHIS Form 7023: FY 1 Oct 2018 -30 Sep 2019**

Registration Number 22-R-0155

Customer number 334734

**Species: Guinea Pigs**

The study objective (b) (4)

. The tests are required as proof of vaccine potency in each serial of vaccine produced. Two thousand six hundred twenty-seven (2,627) animals experienced acute systemic toxic effects or lameness from the administration of challenge material. Use of pain-relieving drugs may invalidate the scientific validity of the results as per 9CFR regulations.

**Explanation for Animals Listed in Category E-APHIS Form 7023: FY 1 Oct 2018 -30 Sep 2019**

Registration Number 22-R-0155

Customer number 334734

**Species: Dog**

Seven (7) dogs used in (b) (4) experienced short-term clinical disease. The clinical signs were consistent with (b) (4). Pain relieving drugs were not used as they would have adversely affected the scientific validity of the study.

Sixty-three (63) dogs were used in (b) (4) to evaluate safety and efficacy of novel therapeutic compounds. Post compound reactions were signs that would be expected (b) (4). Pain relieving drugs were not used as they would have adversely affected the scientific validity of the studies. Seven (7) dogs deceased prior to euthanasia, twenty-five (25) reached IACUC determined humane endpoints and were euthanized, while the rest remained on study under veterinary oversight.